Research programme: anticancer antibodies - Xerion
Latest Information Update: 08 May 2008
At a glance
- Originator Xerion Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Jul 2003 Preclinical trials in Cancer in USA (unspecified route)